FZ007-119 / Guangzhou Fermion - LARVOL DELTA

Fermion’s TYK2 JH2 Inhibitor FZ007-119 Granted IND Approval by China NMPA (PRNewswire) - "Guangzhou Fermion Technology Co., Ltd...is pleased to announce the approval of the Investigational New Drug (IND) for its TYK2 JH2 inhibitor, FZ007-119, by the China National Medical Products Administration...Preclinical studies of FZ007-119 have demonstrated high selectivity for JAK1-3, indicating significant potential for clinical benefits, such as improved clinical efficacy and enhanced safety of use. Its exceptional selectivity positions FZ007-119 as a potential Best in Class (BIC) candidate within its category...FZ007-119's selectivity for JAK1-3 exceeds that of Deucravacitinib by a wide margin, thus holding the potential to become a Best in Class TYK2 JH2 inhibitor."

New trial • Preclinical • Immunology • Psoriasis